Bellus Health Inc. (BLU.TO) 0.82 $BLU.TO
BELLUS Health reports results for year ended December 31, 2013
CNW Group - Wed Feb 26, 6:00AM CST
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"
, a drug development company focused on rare diseases, today reported its financial and operating results for the year ended December 31, 2013.
BELLUS Health provides update on KIACTA(TM) Phase III orphan drug study
CNW Group - Thu Jan 09, 6:00AM CST
-KIACTATM Study Expected to Conclude Earlier than Anticipated -
BELLUS Health reports results for third quarter ended September 30, 2013
CNW Group - Tue Nov 05, 4:00PM CST
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company" today reported its financial and operational results for the third quarter ended September 30, 2013.
BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis
CNW Group - Mon Oct 28, 6:00AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company", a drug development company focussed on rare diseases, today announced an agreement with AmorChem Holdings Inc. ("AmorChem" to develop drug candidates for the treatment of AL amyloidosis.
BELLUS Health Out-Licenses VIVIMIND, BLU8499 and Its Analogs
CNW Group - Wed Oct 23, 5:00AM CDT
-VIVIMIND Rights Licensed to Specialty Pharma FB Health-
BELLUS Health announces closing of the acquisition of Thallion Pharmaceuticals
CNW Group - Thu Aug 15, 6:40AM CDT
- PIPELINE NOW FEATURES TWO CLINICAL-STAGE RARE DISEASE DRUG CANDIDATES -
Thallion Pharmaceuticals Announces Cash Component of $0.1889 Per Share
Marketwire - Fri Aug 09, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a notice to BELLUS Health indicating that Thallion has negotiated a final and binding agreement with Iberville Development Leasing Limited pursuant to which the latter has agreed to fully, finally and irrevocably release Thallion from its obligations under the lease dated December 2, 2010, in exchange for the payment of an amount which is less than the provision for the termination of such lease included in the minimum net cash component announced on August 2, 2013. The cash component of the consideration payable on the effectiveness of the Arrangement has been increased by $0.0124 per common share resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being $0.1889 per common share.
BELLUS Health reports results for second quarter ended June 30, 2013
CNW Group - Wed Aug 07, 6:00AM CDT
- KIACTATM intellectual property position further strengthened by granting of new US patent -
Thallion Announces Shareholder Approval for Plan of Arrangement and Date and Time for the Motion for Final Court Order
Marketwire - Tue Aug 06, 4:00PM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that the shareholders of Thallion approved the previously announced plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health at the annual and special meeting of the shareholders held today in Montreal (the "Meeting". Pursuant to the Arrangement, the Shareholders will receive cash consideration of at least $0.1765 per common share, and one contingent value right ("CVR" per common share, entitling the holder thereof to: (A) its pro rata share of 100% of any additional purchase price consideration to be received from Premium Brands Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), (
its pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS Health, capped at $6.5 million (or $0.1812 per CVR), and Copyright its pro rata share of 100% of any net proceeds generated from the licensing, selling or otherwise commercializing of (i) diagnostic products or services using certain Caprion Proteomics Inc. products, and (ii) all issued patents or pending patents pertaining to such Caprion Proteomics Inc. products, in respect of which Thallion has an ownership interest or monetary entitlement.
RETRANSMISSION/Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 9:54AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component".
Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component".
KIACTA(TM) Granted Orphan Drug Status in Japan
CNW Group - Tue Jul 23, 6:00AM CDT
- Japanese drug development grant also received for KIACTATM -
RETRANSMISSION: BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Fri Jul 12, 4:25PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health.
BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Wed Jul 10, 6:01AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health.
BELLUS Health reports results for year ended December 31, 2013
CNW Group - Wed Feb 26, 6:00AM CST
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"
, a drug development company focused on rare diseases, today reported its financial and operating results for the year ended December 31, 2013. BELLUS Health provides update on KIACTA(TM) Phase III orphan drug study
CNW Group - Thu Jan 09, 6:00AM CST
-KIACTATM Study Expected to Conclude Earlier than Anticipated -
BELLUS Health reports results for third quarter ended September 30, 2013
CNW Group - Tue Nov 05, 4:00PM CST
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"
today reported its financial and operational results for the third quarter ended September 30, 2013. BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis
CNW Group - Mon Oct 28, 6:00AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"
, a drug development company focussed on rare diseases, today announced an agreement with AmorChem Holdings Inc. ("AmorChem" to develop drug candidates for the treatment of AL amyloidosis. BELLUS Health Out-Licenses VIVIMIND, BLU8499 and Its Analogs
CNW Group - Wed Oct 23, 5:00AM CDT
-VIVIMIND Rights Licensed to Specialty Pharma FB Health-
BELLUS Health announces closing of the acquisition of Thallion Pharmaceuticals
CNW Group - Thu Aug 15, 6:40AM CDT
- PIPELINE NOW FEATURES TWO CLINICAL-STAGE RARE DISEASE DRUG CANDIDATES -
Thallion Pharmaceuticals Announces Cash Component of $0.1889 Per Share
Marketwire - Fri Aug 09, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion"
(TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a notice to BELLUS Health indicating that Thallion has negotiated a final and binding agreement with Iberville Development Leasing Limited pursuant to which the latter has agreed to fully, finally and irrevocably release Thallion from its obligations under the lease dated December 2, 2010, in exchange for the payment of an amount which is less than the provision for the termination of such lease included in the minimum net cash component announced on August 2, 2013. The cash component of the consideration payable on the effectiveness of the Arrangement has been increased by $0.0124 per common share resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being $0.1889 per common share. BELLUS Health reports results for second quarter ended June 30, 2013
CNW Group - Wed Aug 07, 6:00AM CDT
- KIACTATM intellectual property position further strengthened by granting of new US patent -
Thallion Announces Shareholder Approval for Plan of Arrangement and Date and Time for the Motion for Final Court Order
Marketwire - Tue Aug 06, 4:00PM CDT
Thallion Pharmaceuticals Inc. ("Thallion"
(TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that the shareholders of Thallion approved the previously announced plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health at the annual and special meeting of the shareholders held today in Montreal (the "Meeting". Pursuant to the Arrangement, the Shareholders will receive cash consideration of at least $0.1765 per common share, and one contingent value right ("CVR" per common share, entitling the holder thereof to: (A) its pro rata share of 100% of any additional purchase price consideration to be received from Premium Brands Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), ( its pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS Health, capped at $6.5 million (or $0.1812 per CVR), and Copyright its pro rata share of 100% of any net proceeds generated from the licensing, selling or otherwise commercializing of (i) diagnostic products or services using certain Caprion Proteomics Inc. products, and (ii) all issued patents or pending patents pertaining to such Caprion Proteomics Inc. products, in respect of which Thallion has an ownership interest or monetary entitlement. RETRANSMISSION/Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 9:54AM CDT
Thallion Pharmaceuticals Inc. ("Thallion"
(TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component". Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion"
(TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement" pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component". KIACTA(TM) Granted Orphan Drug Status in Japan
CNW Group - Tue Jul 23, 6:00AM CDT
- Japanese drug development grant also received for KIACTATM -
RETRANSMISSION: BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Fri Jul 12, 4:25PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health"
and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health. BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Wed Jul 10, 6:01AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health"
and Thallion Pharmaceuticals Inc. ("Thallion" (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment" to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement" involving the acquisition of Thallion by BELLUS Health. 
